Diminished DYRK2 sensitizes hormone receptor-positive breast cancer to everolimus by the escape from degrading mTOR
详细信息 查看全文
- 作者：Rei Mimotoa ; b ; Naoe T. Nihiraa ; d ; Shinichi Hirookac ; Hiroshi Takeyamab ; Kiyotsugu Yoshidaa ; kyoshida@jikei.ac.jp" class="auth_mail" title="E-mail the corresponding author
- 关键词：Breast cancer ; mTOR pathway ; DYRK2 ; Everolimus
- 刊名：Cancer Letters
- 出版年：2017
- 出版时间：1 January 2017
- 年：2017
- 卷：384
- 期：Complete
- 页码：27-38
- 全文大小：2354 K
文摘
- •
mTOR pathway is activated in hormone receptor-positive DYRK2-depleted cells.
- •
Everolimus is effective against metastatic breast cancers with low DYRK2 expression.
- •
DYRK2 phosphorylates mTOR at Thr631 to promote the degradation of mTOR.